The global nuclear medicine diagnostic (PET and SPECT) market accounted to USD 11.01 billion in 2016 and is estimated to touch USD 19.48 billion in 2021, at an estimated compound annual growth rate (CAGR) of 12.08 % during the forecast period. Major factors for the growth of the market are increasing use of SPECT and PET analysis in radiopharmaceuticals, increased awareness of people for radiopharmaceuticals, and ready availability of radiopharmaceuticals.
Request a sample of Market Research Report @ http://www.orbisresearch.com/contacts/request-sample/255842
Novel applications such as Alzheimers and continually expanding oncology application segment also drive the market. Till now, SPECT imaging was the mainstream modality for nuclear medicine applications like nuclear cardiology procedures. However, the trend is soon going to flip upside down because of global shortage of molybdenum-99 isotope which is in turn will lead to shortage of Technetium-99, which is the daughter product of molybdenum. Hence, PET imaging products which includes hybrid PET-CT scanners holds a potential market size in coming years. The cost associated with PET-CT service contract is usually 105 of the system purchase price annually and can be as high as $275,000 per year. The emerging market trend is fusion of nuclear imaging with different diagnostic imaging products such as PET/CT, SPECT/CT, and MRI/PET. This provides full gamut of imaging scans through the same unit and at the same time. PET market is expected to witness more growth compared to SPECT imaging as it provides higher resolution images and the lack of availability of technetium-99m is propelling industry to look for alternative diagnostic procedures.
Analyzing the application segment of SPECT and PET, PET is majorly being used in oncology because of good quality of imaging. While, SPECT is majorly used in cardiology segment accounting for almost 90% of the market share in cardiology. North America has 5729 PET procedures while the number of PET procedures in Asia-Pacific region is 369636 owing to the increased demand of nuclear medicine diagnostic procedures in developing nations. Market is segmented into two major segments SPECT (Technetium-99m (TC-99m), Thallium-201 (TL-201), Iodine (I-123) and others) and PET (Fluorine-18, Rubidium-82 (RB-82) and others). By application market is segmented into SPECT (cardiology, lymphoma, thyroid, neurology and others) and PET(oncology, cardiology, neurology and others).By geography market is segmented into North America, Europe and Asia-Pacific etc. North America accounts for the highest share of the global nuclear medicine diagnostic market; followed by Europe and Asia-Pacific. Asian countries are expected to show a growing trend in diagnostic sector because of increasing diagnostic procedure demand and rise in medical device industry.Major players in the market are Cardiarc Ltd., Digirad Corporation, Gamme Medica Inc., GE healthcare, Hologic Inc. etc. Mergers and acquisitions of small and medium sized manufacturers to enter in overseas market is another strategy adopted by multinational players.,
Browse Full Market Research Report@ http://www.orbisresearch.com/reports/index/global-nuclear-imaging-market-by-type-application-and-region-industry-analysis-size-share-growth-trends-and-forecasts-2016-2021
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: email@example.com